The potential utility of PPT1 blockade in conjunction with ICIs is being evaluated in an ongoing phase IIb study using GNS561/ezurpimtrostat, a novel inhibitor of PPT1, which has shown promising anti-tumor activity in pre-clinical models (NCT05448677) (161, 162). This evidence concerns the gene PPT1 and neoplasm.